Bladder and Kidney Cancer: Intravesical Therapy, Immunotherapy and TKIs
Two cancers sit a few centimetres apart in the urinary tract, yet their drug stories could hardly be more different. The bladder is a hollow bag you can fill with a drug and drain an hour later — so its earliest cancers are treated by pouring medicine straight in, bathing the tumour while the rest of the body barely notices. The kidney's cancer refused chemotherapy entirely, and forced oncologists to attack its biology instead — the faulty gene that makes it grow its own blood supply. One organ taught us local therapy; the other taught us targeted therapy. Together they are a masterclass in matching the route and the mechanism to the tumour.
A 63-year-old man notices painless blood in his urine. Cystoscopy finds a small frond-like tumour on the bladder wall; the pathologist calls it high-grade, non-muscle-invasive urothelial carcinoma. He is not sent for chemotherapy through a vein. Instead, in the clinic, a catheter is passed and his bladder is slowly filled with a suspension of live, weakened tuberculosis-related bacteria — BCG. He holds it for two hours, turning from side to side, then voids it into a toilet treated as biohazardous. Over the following weeks he feels the price: burning on passing urine, urinary frequency, a low-grade fever. This is not an infection to be cured — it is the treatment working, a deliberate immune fire lit inside the bladder to stop the cancer coming back. A century-old vaccine against tuberculosis has become one of the oldest and most effective cancer immunotherapies we have.
The bladder's gift: a route you can fill and drain
Most tumours can only be reached through the bloodstream. A superficial bladder tumour can be reached directly. Bladder cancer is usually urothelial (transitional cell) carcinoma, and most cases present while still non-muscle-invasive — confined to the lining, not yet through the muscle wall. This is the one setting where geography changes pharmacology. The bladder is a reservoir with a single outlet, so a drug can be instilled through a catheter, held for an hour or two, then simply voided. This intravesical route bathes the tumour in a high local concentration while systemic absorption stays low — a naturally targeted delivery that spares the patient the nausea, marrow suppression and hair loss of intravenous chemotherapy. It is the same principle that makes topical drugs elsewhere so clean: put the medicine only where the disease is.
Intravesical BCG: a live vaccine turned cancer therapy
The cornerstone of high-risk non-muscle-invasive disease is intravesical BCG — Bacillus Calmette–Guérin, a live attenuated strain of Mycobacterium bovis, the very organism used as the tuberculosis vaccine. Instilled into the bladder, it does not act as a cytotoxic drug at all. It provokes a vigorous local immune and inflammatory response: mycobacteria are taken up by urothelial and immune cells, antigens are presented, and a flood of T cells, macrophages and cytokines is recruited into the bladder wall. That non-specific immune activation clears residual tumour cells and, crucially, reduces both recurrence and progression to muscle-invasive disease better than chemotherapy instillation. BCG is, in effect, the original cancer immunotherapy — deployed decades before anyone spoke of checkpoint inhibitors, and its mechanism ties directly to the Antimicrobials and Immunology sections, where mycobacterial immunity and the TB vaccine itself are taught.
The therapeutic effect and the toxicity are the same fire, and BCG remains a live organism throughout. Because the mechanism is deliberate inflammation, mild cystitis — dysuria, frequency, haematuria, low-grade fever — is expected and even reassuring. But BCG is a live pathogen, and that carries real hazards. If it enters the bloodstream — through a traumatic catheterisation, active bleeding, or instillation too soon after resection — it can cause disseminated BCG-osis, a systemic infection resembling miliary tuberculosis, treated with anti-tuberculous drugs. For the same reason BCG is contraindicated in the immunosuppressed and during macroscopic haematuria, must be handled with the precautions due any live vaccine, and voided urine is decontaminated. The lesson is the mirror image of chemotherapy: here the drug is alive, and respecting that is the whole safety story.
Think of the bladder as a fish tank with a drain. To treat something growing on the glass walls, you don't medicate the fish's bloodstream — you tip the treatment straight into the water, let it soak the walls, then pull the plug. Intravesical chemotherapy is a mild disinfectant poured into that tank: it kills stray cells on contact. BCG is different — it is like deliberately seeding the tank with a harmless algae that the tank's own guardians rush to attack, and in the fury of that clean-up they scrub the cancer off the glass too. The water barely reaches the fish; the whole battle stays inside the tank.
Intravesical chemotherapy: mitomycin C and gemcitabine
The other intravesical option is cytotoxic chemotherapy instilled the same way. A single dose of mitomycin C — an alkylating antibiotic that cross-links DNA — given into the bladder immediately after tumour resection kills floating cells before they can re-implant, cutting recurrence in lower-risk tumours. Gemcitabine, an antimetabolite, is used similarly and increasingly where BCG supply is short or has failed. Because these agents are poorly absorbed across the urothelium, systemic toxicity is minimal; the main adverse effect is chemical cystitis. The choice is essentially strategic: intravesical chemotherapy for lower-risk disease and immediate post-resection prophylaxis, BCG immunotherapy for higher-risk disease where preventing progression matters most. These cytotoxic mechanisms are covered in full in the Oncology chapter on alkylating agents and antimetabolites.
- Most bladder cancer is urothelial and non-muscle-invasive at diagnosis — treatable via the intravesical route.
- Intravesical delivery = high local drug concentration, minimal systemic exposure and toxicity.
- BCG is live attenuated M. bovis — it works by provoking a local immune/inflammatory response, not by direct cytotoxicity.
- BCG reduces both recurrence and progression in high-risk non-muscle-invasive disease.
- As a live organism BCG risks cystitis and, rarely, systemic BCG-osis — contraindicated in immunosuppression and gross haematuria.
- Intravesical mitomycin C / gemcitabine are the chemotherapy alternatives for lower-risk disease and post-resection prophylaxis.
When the tumour invades: systemic therapy for advanced bladder cancer
Once urothelial cancer invades the muscle or spreads, local instillation is no longer enough and treatment turns systemic. The traditional backbone is cisplatin-based chemotherapy, given as neoadjuvant treatment before cystectomy or for metastatic disease — its DNA-cross-linking mechanism, and its cost in nephrotoxicity, ototoxicity and emesis, are detailed in the Oncology platinum chapter. Fitness for cisplatin often hinges on renal function, so many patients need alternatives. Three modern classes have reshaped the field. Immune checkpoint inhibitors — pembrolizumab, atezolizumab, nivolumab — release the brakes on the patient's own T cells and are now used in the metastatic setting and increasingly as maintenance; their PD-1/PD-L1 mechanism and their immune-related toxicities are covered in the Oncology immunotherapy chapter (the same chapter that lists bladder cancer among the responsive tumours).
Two further agents are precision tools — one a guided missile, the other keyed to a specific mutation. Enfortumab vedotin is an antibody–drug conjugate: a monoclonal antibody against Nectin-4 (highly expressed on urothelial cells) tethered to a potent microtubule-poisoning payload. The antibody homes to the tumour and delivers the toxin selectively inside the cancer cell — the guided-missile logic of ADCs explained in the Oncology chapter, with peripheral neuropathy and skin reactions as signature effects. Finally, erdafitinib is an FGFR inhibitor, an oral tyrosine kinase inhibitor for the subset of urothelial tumours driven by FGFR2/3 alterations — a genuinely biomarker-selected therapy, prescribed only after the tumour is tested. Together they show how advanced bladder cancer has moved from one blunt chemotherapy to a menu chosen by fitness, biomarker and mechanism.
Platinum chemotherapy: cisplatin (gemcitabine–cisplatin) — neoadjuvant and first-line metastatic, renal-function permitting. Checkpoint inhibitors: pembrolizumab, atezolizumab, nivolumab — metastatic and maintenance settings. Antibody–drug conjugate: enfortumab vedotin (anti–Nectin-4 + microtubule toxin). FGFR inhibitor: erdafitinib — only for FGFR2/3-altered tumours. The direction of travel is combinations — enfortumab vedotin with pembrolizumab has become a leading first-line regimen for advanced disease, pairing a targeted delivery with released immunity.
Renal cell carcinoma: the cancer that refused chemotherapy
Renal cell carcinoma (RCC) is the great exception in oncology: it is classically chemotherapy-resistant. Conventional cytotoxic drugs barely dent it, partly because renal tubular cells naturally express drug-efflux pumps. That resistance forced a different question — not "what poison kills this cell?" but "what makes this cell grow?" The answer lies in its biology. Most clear-cell RCC carries a defective VHL (von Hippel–Lindau) gene. VHL normally tags hypoxia-inducible factor (HIF) for destruction; when VHL fails, HIF accumulates as though the cell were permanently starved of oxygen, and drives relentless production of VEGF — the master growth factor for new blood vessels. The tumour, in effect, is stuck screaming for a blood supply. Every targeted drug in RCC attacks a link in that VHL → HIF → VEGF → angiogenesis chain.
This is the same VEGF pathway that the Ophthalmology section attacks in wet macular degeneration — there, anti-VEGF antibodies are injected into the eye to stop leaky new vessels ruining the retina. Same molecular target, opposite spatial trick: the eye receives the drug by direct intravitreal injection into a tiny closed space, while RCC needs a drug that travels the whole bloodstream to reach a scattered tumour. The bladder and the eye both exploit a local route; the kidney's cancer cannot, so it accepts systemic exposure as the price of hitting VEGF everywhere it hides.
Anti-angiogenic tyrosine kinase inhibitors
The workhorse of RCC is a pill that starves the tumour of its blood supply. The mainstay targeted drugs are oral tyrosine kinase inhibitors (TKIs) aimed at the VEGF receptor and related kinases: sunitinib, pazopanib, cabozantinib and axitinib. By blocking VEGFR signalling on endothelial cells, they choke off the new-vessel growth the tumour depends on — anti-angiogenic therapy rather than direct cell killing. Because these are multi-target kinase inhibitors, their side-effect profile is a class fingerprint that turns up repeatedly in exams: hypertension (the direct consequence of removing VEGF's vasodilatory, nitric-oxide-mediated tone — linking to the Cardiovascular section on how antihypertensives are then required), hand–foot syndrome (painful palmar-plantar erythema), hypothyroidism (so thyroid function must be monitored — a tie to the Endocrine section), proteinuria, fatigue and diarrhoea. Cabozantinib and axitinib also block other kinases (MET, AXL) implicated in escape from pure VEGF blockade. The broader kinase-inhibitor mechanism is taught in the Oncology targeted-therapy chapter.
mTOR inhibitors and checkpoint immunotherapy
A second targeted class hits the same growth machinery further downstream: the mTOR inhibitors everolimus and temsirolimus. mTOR is an intracellular kinase that drives cell growth and, importantly, HIF translation — so blocking it dampens the very angiogenic signal RCC lives on. These are the same molecules used as immunosuppressants after transplantation (a cross-link to the Immunology section), and they carry a metabolic signature: hyperglycaemia, hyperlipidaemia, mouth ulcers and pneumonitis. But the most important modern shift in RCC is immunotherapy. Kidney cancer is highly immune-responsive, and checkpoint inhibitors have moved to the front line — typically in combination. Two winning strategies dominate: dual checkpoint blockade with ipilimumab plus nivolumab (anti–CTLA-4 plus anti–PD-1), and a checkpoint inhibitor paired with a VEGFR TKI (for example pembrolizumab with axitinib), marrying immune release to anti-angiogenesis. The checkpoint mechanism and its immune-related adverse events are covered in depth in the Oncology immunotherapy chapter; here the lesson is that RCC, once chemo-resistant and nearly untreatable when metastatic, became a showcase for both targeted and immune therapy.
- RCC is classically chemotherapy-resistant — it is treated by targeting its biology, not by cytotoxic poisoning.
- The core driver is VHL loss → HIF accumulation → VEGF-driven angiogenesis; every targeted drug attacks this axis.
- Anti-angiogenic VEGFR TKIs (sunitinib, pazopanib, cabozantinib, axitinib) are the workhorse targeted agents.
- TKI class effects: hypertension, hand–foot syndrome, hypothyroidism, proteinuria, fatigue and diarrhoea.
- mTOR inhibitors (everolimus, temsirolimus) block HIF-driven growth; watch for hyperglycaemia and pneumonitis.
- Checkpoint immunotherapy is now front-line, usually combined (ipilimumab+nivolumab, or a checkpoint inhibitor + a TKI).
- Treating BCG-induced cystitis and low-grade fever as an ordinary urinary infection. Mild symptoms are the expected therapeutic reaction; the real alarm is systemic BCG-osis — high or persistent fever needs anti-tuberculous treatment, not a routine antibiotic.
- Instilling intravesical BCG in the wrong setting — after traumatic catheterisation, during gross haematuria, or in an immunosuppressed patient — where a live organism can seed the bloodstream and cause disseminated infection.
- Reaching for classical cytotoxic chemotherapy in metastatic renal cell carcinoma. RCC is chemo-resistant; the correct answer is a VEGFR TKI, an mTOR inhibitor, or checkpoint immunotherapy — and remember to monitor blood pressure and thyroid function on a TKI.
A 68-year-old man with high-grade non-muscle-invasive urothelial carcinoma is treated with intravesical BCG. Three weeks later he has mild dysuria and urinary frequency with a temperature of 37.6°C. What does this most likely represent?
- The bladder allows LOCAL intravesical therapy: BCG (live attenuated mycobacteria — immunotherapy that cuts recurrence and progression) and chemotherapy (mitomycin C, gemcitabine) for non-muscle-invasive disease.
- BCG is a live organism — expected cystitis, but risk of systemic BCG-osis; contraindicated in immunosuppression and gross haematuria.
- Muscle-invasive/metastatic bladder cancer goes systemic: cisplatin chemotherapy, checkpoint inhibitors, the ADC enfortumab vedotin, and the FGFR inhibitor erdafitinib for FGFR-altered tumours.
- RCC is chemo-resistant, driven by VHL→HIF→VEGF, so it is treated by targeting angiogenesis: VEGFR TKIs (sunitinib, pazopanib, cabozantinib, axitinib — hypertension, hand–foot, hypothyroidism), mTOR inhibitors (everolimus, temsirolimus), and checkpoint immunotherapy, often in combination.
- Rang & Dale's Pharmacology — Anticancer drugs: targeted therapies and immunotherapy.
- Katzung. Basic & Clinical Pharmacology — Cancer chemotherapy; targeted and biological agents.
- British National Formulary (BNF) — BCG bladder instillation, mitomycin, VEGFR tyrosine kinase inhibitors, mTOR inhibitors.
- EAU (European Association of Urology) Guidelines — Non-muscle-invasive and muscle-invasive bladder cancer; renal cell carcinoma.
- NICE guidelines — Bladder cancer (NG2) and renal cell carcinoma management.
- Choueiri TK, Motzer RJ. Systemic Therapy for Metastatic Renal-Cell Carcinoma. New England Journal of Medicine.
